In Mouse Studies, New Hope Against a Dangerous Complication of Pregnancy

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 13, 2024.

By Dennis Thompson HealthDay Reporter

FRIDAY, Dec. 13, 2024 -- The same technology behind COVID vaccines might be able to protect both the mother and child from a dangerous complication of pregnancy.

A new mouse study published Dec. 11 in the journal Nature shows that injections based on that vaccine platform reduced the risk of preeclampsia in lab mice.

Preeclampsia is persistent high blood pressure that occurs during pregnancy or after giving birth. It can threaten the life of both the mother and baby, or leave the mom with severe organ damage.

The experimental injection “was able to deliver an mRNA therapeutic that reduced maternal blood pressure through the end of gestation and improved fetal health and blood circulation in the placenta,” said researcher Kelsey Swingle, a doctoral student in bioengineering at the University of Pennsylvania School of Engineering and Applied Science. “Additionally, at birth we saw an increase in litter weight of the pups, which indicates a healthy mom and healthy babies."

Preeclampsia affects 3% to 5% of pregnancies, researchers said in background notes. There’s no cure for the condition; instead, women take blood pressure medication or stay on bed rest.

Preeclampsia arises due to insufficient blood flow to the placenta, which causes a mom’s blood pressure to rise while restricting blood flow to the fetus.

Researchers figured that a drug designed to get into the placenta despite the restricted blood flow might help resolve the condition.

To design that drug, researchers turned to the particles used to deliver mRNA COVID vaccines.

The mRNA that creates an immune response to COVID is delivered inside lipid nanoparticles (LNP), which are microscopic balls of fatty material. These particles dissolve inside the human body, releasing the payload they’re carrying.

Swingle examined 98 different lipid nanoparticles, assessing their ability to reach the placenta of pregnant mice.

Swingle finally landed on a particle that provided 100-fold better mRNA delivery to the placenta than an FDA-approved lipid nanoparticle.

The results showed that the one-time injection cured mice with preeclampsia until the end of their pregnancy.

“At this stage in our research, we would bring this LNP to larger animals such as rats and guinea pigs first, to determine how well it works in the ‘gold standard’ models of preeclampsia before we could advance this work to human trials,” Swingle said in a university news release.

“Testing our LNP on guinea pigs will be particularly interesting, as their placenta closely resembles a human’s and their gestational period is longer, up to 72 days,” Swingle added. “We will be asking the questions ‘How many doses do these animals need?’ ‘Will the minimum effective dose change?’ and ‘How well does our current LNP work in each?’”

This research also shows the potential for using lipid nanoparticles to deliver cures for other diseases and disorders, Swingle concluded.

Sources

  • University of Pennsylvania, news release, Dec. 11, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-12-14 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords